Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by qwerty22on Dec 01, 2021 11:45am
69 Views
Post# 34185228

RE:RE:RE:RE:Hiv at 40 video

RE:RE:RE:RE:Hiv at 40 video

Also emphasizes the extent to which both drugs depended on each other thru the clinical development process. I wish that would extend to the experience in the clinic.


qwerty22 wrote:

Found this new research while searching.

https://www.natap.org/2021/EACS/EACS_29.htm

Not sure what the motivation was for VIIV to do this work but I guess it suggests Trogarzo and Fos are non-inferior to each other.

 

Wino115 wrote: Yes, professional production and good PR, even if the THTX guy is talking like the reporter is his hard to hear grandmother from a foreign country.

 

 

qwerty22 wrote:


In case people don't know ITN is the leading commercial network TV company in the UK, behind the bbc. Possibly the leading production company in uk TV. It's a helluva step up from that recent video they put out!
 

 




<< Previous
Bullboard Posts
Next >>